Results 331 to 340 of about 95,577 (390)
Dynamics of cortico-subthalamic neuronal patterns during dyskinesia in Parkinson’s disease
Habets J +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
JAMA: The Journal of the American Medical Association, 1970
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery
Pharmaceutical development and technology (Print), 2020Parkinson’s disease (PD) is a neurodegenerative disease which is characterized by the loss of dopaminergic neurons in the brain. Levodopa is the drug of choice in the treatment of PD but it exhibits low oral bioavailability (30%) and very low brain ...
S. Arısoy +5 more
semanticscholar +1 more source
Journal of Neurology, 2004
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
Clinical Pharmacology & Therapeutics, 1971
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources
Journal of Neurology, 2010
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela Contin, Paolo Martinelli
openaire +2 more sources
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela Contin, Paolo Martinelli
openaire +2 more sources
The American Journal of Nursing, 1974
chronic care facility with no hope of improvement. Parkinsonism is a fairly common, disabling, movement disorder caused by dysfunction of the extrapyramidal system. There are 90 to 110 cases per 100,000 people and an annual incidence of 20 cases per 100,000 people in the United States(1).
openaire +3 more sources
chronic care facility with no hope of improvement. Parkinsonism is a fairly common, disabling, movement disorder caused by dysfunction of the extrapyramidal system. There are 90 to 110 cases per 100,000 people and an annual incidence of 20 cases per 100,000 people in the United States(1).
openaire +3 more sources
Neurology, 1974
We feel it prudent to sound a note of caution about the use of levodopa in patients with known melanomas or with pigmented lesions. Levodopa was administered to three of our patients with Parkinson9s disease and known melanomas or pigmented lesions.
Jerome L. Shupack, Abraham Lieberman
openaire +3 more sources
We feel it prudent to sound a note of caution about the use of levodopa in patients with known melanomas or with pigmented lesions. Levodopa was administered to three of our patients with Parkinson9s disease and known melanomas or pigmented lesions.
Jerome L. Shupack, Abraham Lieberman
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1979
To the Editor.— Based on personal experience with a single case of Parkinson's disease and malignant melanoma and an incomplete review of the literature, Sober and Wick (240:554, 1978) conclude that levodopa should be administered to patients with Parkinson's disease who have a history of melanoma.
Joseph Fermaglich, Peyton Delaney
openaire +3 more sources
To the Editor.— Based on personal experience with a single case of Parkinson's disease and malignant melanoma and an incomplete review of the literature, Sober and Wick (240:554, 1978) conclude that levodopa should be administered to patients with Parkinson's disease who have a history of melanoma.
Joseph Fermaglich, Peyton Delaney
openaire +3 more sources